Jeremy Ariey-Bonnet et al., 2020-12: In silico target prediction followed by biochemical validation identifying mebendazole as a direct MAPK14/p38-alpha inhibitor, with activity in glioblastoma cells.
Mebendazole could inhibit the activity of these kinases in vitro in a dose-dependent manner, with a high potency against MAPK14 (IC50 = 104 ± 46 nm).
Jeremy Ariey-Bonnet et al., 2020-12: In silico target prediction followed by biochemical validation identifying mebendazole as a direct MAPK14/p38-alpha inhibitor, with activity in glioblastoma cells. Study type: in silico prediction plus recombinant kinase assays and glioblastoma cell lines. N: not applicable. Country: France (CNRS/INSERM, Institut Paoli Calmettes, Marseille). Dose: IC50 104 +/- 46 nM against MAPK14; cellular IC50 288 nM to 2.1 micromolar in glioblastoma lines. Funder: not stated in the record. Declared conflicts: 'The authors declare no conflict of interest.' Comparator: ABL1 and MAPK1/ERK2 kinases tested in parallel.
